Poseida Therapeutics Presents Preclinical Solid Tumor Data for P-PSMA-101, a CAR-T Therapy Predominantly Comprised of Stem Cell Memory T Cells, at the Prostate Cancer Foundation Annual Retreat

Poseida Therapeutics Inc. (“Poseida”), a San Diego-based clinical-stage company translating best-in-class gene therapy technologies into lifesaving cell therapies, today presented preclinical data on P-PSMA-101, the company’s PSMA-specific chimeric antigen receptor T cell (CAR-T) stem cell memory drug candidate for the treatment of prostate cancer, showing potent anti-tumor activity, a persistent and durable response, and no T-cell exhaustion observed. This preclinical study demonstrated that Poseida’s advanced CAR-T cell therapy could completely eliminate solid tumors in a previously incurable preclinical model of prostate cancer, and was selected for oral presentation today at the 24th Prostate Cancer Foundation Annual Retreat in Washington DC.

Read the full press releaseCompany website